An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Nov 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cemiplimab (Primary) ; INO 5401 (Primary) ; INO 9012 (Primary) ; Temozolomide (Primary)
Indications Glioblastoma
Focus Adverse reactions
Sponsors Inovio Pharmaceuticals

22 Nov 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
22 Nov 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
14 May 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com